Day: March 10, 2021

TORONTO, March 10, 2021 (GLOBE NEWSWIRE) — WPT Industrial Real Estate Investment Trust (the “REIT”) (TSX: WIR.U; WIR.UN; OTCQX: WPTIF) announced today its results for the three months and year ended December 31, 2020. All dollar amounts are stated in U.S. funds.Highlights:Collected 99.8% of billed rent for the quarter, continuing the REIT’s record of strong rent collectionsFFO/unit increased 17.6% and AFFO/unit increased 25.4% over the same period last yearSame properties NOI(1) increased 3.1%Occupancy of 98.2%Generated $1.8 million of private capital fee revenueIncreased 2021 annual private capital fee guidance to a range of $10 million to $14 millionCompleted six off-market acquisitions during the quarter and following quarter end, including two distribution properties totaling 348,918 square feet in Northern New Jersey and four...

THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR RELEASE, PUBLICATION OR DISSEMINATION, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES.TORONTO, March 10, 2021 (GLOBE NEWSWIRE) — Blockchain Foundry Inc. (“BCF” or the “Company”) (CSE:BCFN), a leading North American blockchain development firm, is pleased to announce that it has closed its previously announced private placement of equity securities (the “Private Placement”). The Private Placement was for gross proceeds of approximately CAD$10,055,000 and consisted of the sale of 29,792,595 common shares (“Common Shares”) and warrants to purchase up to 29,792,595 Common Shares (“Warrants”), at a purchase price of CAD$0.3375 per Common Share and associated Warrant. The Warrants have an exercise price of...

SAN DIEGO, March 10, 2021 (GLOBE NEWSWIRE) — Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, announced today that four abstracts featuring three of its drug candidates will be presented at the American Association for Cancer Research (AACR) annual meeting, which will convene virtually from April 10-14.For lead drug candidate, repotrectinib, two poster presentations will highlight new preclinical combination data with MEK and MEK/Raf inhibitors, as well as repotrectinib’s potency against wildtype and TRKC A/B/C as compared to approved TRK inhibitors. For MET/SRC/CSF1R inhibitor, TPX-0022, the company will present preclinical data demonstrating potential utility in combination with immune checkpoint inhibitors. For its newest...

Transaction achieves record low spread to benchmark rates, inception-to-dateSAN FRANCISCO, March 10, 2021 (GLOBE NEWSWIRE) — Sunrun (Nasdaq: RUN), the nation’s leading home solar, battery storage and energy services company, today announced it has priced a securitization of leases and power purchase agreements, known as Sunrun’s solar-as-a-service offering.“The market increasingly recognizes the high quality of residential solar assets and our industry-leading performance,” said Ed Fenster, Sunrun co-Founder and Executive Chairman. “Our strong performance over the last year has allowed us to enjoy yet another step down in capital costs and enhances our ability to raise capital at increasingly attractive rates.”The securitization consists of a single-tranche of A- rated notes with a $201 million initial balance, representing an 80.0%...

AURORA, OHIO, March 10, 2021 (GLOBE NEWSWIRE) — Pine Technology Acquisition Corp. (the “Company”) today announced the pricing of its initial public offering of 30,000,000 units at $10.00 per unit. The units will be listed on The Nasdaq Capital Market (“Nasdaq”) under the symbol “PTOCU” commencing on March 11, 2021. Each unit consists of one Class A common stock of the Company and one-third of one redeemable warrant, each whole warrant entitling the holder thereof to purchase one Class A common stock at an exercise price of $11.50 per share. Once the securities constituting the units begin separate trading, the Company expects the Class A common stock and warrants will be listed on Nasdaq under the symbols “PTOC” and “PTOCW,” respectively.The Company is sponsored by Pine Technology...

Media ReleaseCopenhagen, Denmark, March 10, 2021      ·Two posters featuring innovative Genmab bispecific antibody programs selected for presentation at AACR Annual Meeting 2021Genmab A/S (Nasdaq: GMAB) announced today that two posters evaluating investigational medicines created using Genmab’s DuoBody®technology will be presented at the American Association for Cancer Research Annual Meeting 2021, taking place virtually April 10-15 and May 17-21. The posters summarize data from a preclinical evaluation of the investigational medicine, epcoritamab (DuoBody-CD3xCD20) in combination with standard of care therapies for the treatment of B-cell lymphomas, and a preclinical mechanism of action evaluation of GEN1042 (DuoBody-CD40x4-1BB). The abstracts have been published on the AACR website and may be accessed via the Online Meeting Planner....

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATESTORONTO, March 10, 2021 (GLOBE NEWSWIRE) — Marathon Gold Corporation (“Marathon” or the “Company”; TSX: MOZ) is pleased to announce that it has filed a final base shelf prospectus (the “Shelf Prospectus”) with the securities regulatory authorities in each of the provinces and territories of Canada.The Shelf Prospectus will enable Marathon to make offerings of up to a total of C$250 million of any combination of common shares, warrants, subscription receipts, units, convertible securities and debt securities during the 25-month period that the Shelf Prospectus, including any amendments thereto, remains valid. The nature, size and timing of any such financings (if any) will depend, in part, on Marathon’s assessment of its requirements for...

Westport, CT, March 10, 2021 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that the Company has been invited to attend the Oppenheimer 31st Annual Healthcare Conference on Thursday, March 18, 2021. Kenneth L. Londoner, Chairman and CEO of BioSig Technologies, will be participating in a virtual fireside chat at 8:00 AM ET. Mr. Londoner will also be available for investor meetings.BioSig’s PURE EP™ System is an advanced signal acquisition and processing platform that sets a new standard in electrophysiology. The system provides essential diagnostic signals with high clinical...

SHREVEPORT, La., March 10, 2021 (GLOBE NEWSWIRE) — Home Federal Bancorp, Inc. of Louisiana (Nasdaq: HFBL) (the “Company”), the holding company for Home Federal Bank (the “Bank”), announced today that its Board of Directors declared a two-for-one stock split in the form of a 100% stock dividend, payable March 31, 2021, to stockholders of record as of March 22, 2021. Under the terms of the stock split, the Company’s stockholders will receive a dividend of one share for every share held on the record date. The dividend will be paid in authorized but unissued shares of common stock of the Company.The par value of the Company’s stock will not be affected by the split and will remain at $0.01 per share. The Company anticipates that the outstanding shares of stock after the split will be increased from approximately...

SAN CARLOS, Calif., March 10, 2021 (GLOBE NEWSWIRE) — Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that long-term interim data from Cohort 2 in the C-144-01 clinical study (NCT02360579) in advanced melanoma has been accepted as an oral presentation in a Clinical Trials Plenary Session at the upcoming American Association for Cancer Research (AACR) 2021 Annual Meeting.Abstract Title: Lifileucel (LN-144), a cryopreserved autologous tumor infiltrating lymphocyte (TIL) therapy in patients with advanced (unresectable or metastatic) melanoma: durable duration of response at 28-month follow upAuthors: Jason Alan Chesney, MD, PhD, et al.Abstract Number: 5329Presentation Number: CT008Session Title: Immunooncology and Cell Therapy TrialsSession...